Characteristics | Indacaterol/glycopyrronium 110/50 μg o.d. | Salmeterol/fluticasone 50/500 μg b.i.d. |
---|---|---|
(n = 1680) | (n = 1682) | |
Age, years | 64.6 ± 7.89 | 64.5 ± 7.70 |
Men, n (%) | 1299 (77.3) | 1258 (74.8) |
COPD severitya, n (%) | ||
Moderate, GOLD 2 | 560 (33.3) | 563 (33.5) |
Severe, GOLD 3 | 973 (57.9) | 981 (58.3) |
Very severe, GOLD 4 | 133 (7.9) | 124 (7.4) |
High risk and more symptoms (Group D) | 1265 (75.3) | 1249 (74.3) |
Current smokers, n (%) | 664 (39.5) | 669 (39.8) |
Number of COPD exacerbations in the previous year, n (%) | ||
1 | 1355 (80.7) | 1355 (80.6) |
≥ 2 | 324 (19.3) | 325 (19.3) |
SGRQ-C total scoreb | 47.3 (15.8) | 47.2 (15.9) |
Post-bronchodilator FEV1, L | 1.2 ± 0.34 | 1.2 ± 0.35 |
Post-bronchodilator FEV1, % predicted | 44.0 ± 9.48 | 44.1 ± 9.43 |
Post-bronchodilator FEV1/FVC, % | 41.7 ± 9.82 | 41.5 ± 9.89 |